Strongyloidiasis
14
0
0
9
Key Insights
Highlights
Success Rate
90% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
7.1%
1 terminated out of 14 trials
90.0%
+3.5% vs benchmark
43%
6 trials in Phase 3/4
11%
1 of 9 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 9 completed trials
Clinical Trials (14)
Combination Therapies for Trichuris Trichiura Infection in Schoolchildren in Honduras
Strongyloidiasis at CHRU Nancy: Evaluation of the Performance of Serological Tests and Disease-associated Characteristics
Better Options for Lymphatic Filariasis Treatment
Delivering a Multi-disease Screening Tool to Migrant Populations
Efficacy and Safety of Emodepside in Adults Infected With Strongyloidiasis Stercoralis
Treatment of Strongyloides Infection
Evaluation of Strongyloidiasis in Ecuador: a fieLd Laboratory Accuracy Study
Adjunctive Ivermectin Mass Drug Administration for Malaria Control
Strongyloides Stercoralis in Bone Marrow Transplant Recipients in the UK
Safety of Co-administration of IDA and Azithromycin for NTDs ( ComboNTDs )
Multiple Versus Single Dose of Ivermectin for the Treatment of Strongyloidiasis
Diagnosis of Neglected Tropical Diseases Among Patients With Persistent Digestive Disorders
Study of Patients With Strongyloides Stercoralis Infection
Effectiveness of Combined Albendazole and Ivermectin Treatment for Intestinal Worm Infections